3-Ethoxybenzamide

Cat. No.: HY-W237019: Data Sheet Handling Instructions
FAQs
Technical Support

3-Ethoxybenzamide is an alkoxybenzamide compound with antibacterial activity and a FtsZ inhibitor that can cross the blood-brain barrier. 3-Ethoxybenzamide distributes widely and rapidly in vivo, rapidly reaches equilibrium between various tissues and blood, and is linearly taken up by hepatocytes. 3-Ethoxybenzamide is completely dependent on hepatic microsomal oxidation for clearance, with salicylamide as its major metabolite. 3-Ethoxybenzamide can be used for the study of bacterial infections.

For research use only. We do not sell to patients.

3-Ethoxybenzamide Chemical Structure

CAS No. : 55836-69-6

Size	Stock	Quantity
1 g	In-stock	Estimated Time of Arrival: December 31
5 g	Get quote
10 g	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity
Purity & Documentation
References
Customer Review

Description

In Vitro

3-Ethoxybenzamide (0.1-1.0 mM; 0.5-10 min) rapidly reaches equilibrium with rat erythrocytes, and its whole blood-plasma partition coefficient equals 1 at all tested concentrations^[1].
3-Ethoxybenzamide undergoes deethylation in rat liver microsomes, with the corrected kinetic parameter being V_max1=0.124 μmol/min/g^[1].
3-Ethoxybenzamide (500-2000 μg/mL) inhibits the bacterial growth of Bacillus subtilis 168, with an MIC of 2000 μg/mL, and induces cell division inhibition at a concentration of 500 μg/mL^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[2]

Cell Line:	Staphylococcus aureus, Bacillus subtilis 168
Concentration:	500-2000 μg/mL
Incubation Time:	/
Result:	Against Staphylococcus aureus and Bacillus subtilis 168 with MIC of 1024 μg/mL and 2000 μg/mL, respectively.

In Vivo

3-Ethoxybenzamide (10-80 mg/kg; i.v.; single bolus) simulated plasma and tissue concentrations in healthy male albino rabbits show strong agreement with observed values at 10 mg/kg and 20 mg/kg intravenous bolus doses, though the 80 mg/kg dose terminal elimination phase cannot be accurately predicted by the model^[1].
3-Ethoxybenzamide (20-100 mg/kg; i.v.; single bolus) simulated plasma and tissue concentrations in healthy 250 g rats show reasonable agreement with observed values across 20 mg/kg, 50 mg/kg, and 100 mg/kg intravenous bolus doses, with minor discrepancies in small intestine and muscle tissue profiles^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	albino (male, 1.7-2.3 kg)^[1]
Dosage:	10 mg/kg; 20 mg/kg; 80 mg/kg
Administration:	i.v.; single bolus
Result:	Showed very good agreement between simulated and observed plasma concentrations at 10 mg/kg and 20 mg/kg doses. Systemically higher observed plasma concentrations than simulated values in the terminal elimination phase at 80 mg/kg dose. Showed general agreement between simulated and observed tissue concentrations in brain, kidney, and liver at 20 mg/kg dose, despite some variability in measured tissue levels.

Animal Model:	250 g body weight^[1]
Dosage:	20 mg/kg; 50 mg/kg; 100 mg/kg
Administration:	i.v.; single bolus
Result:	Predicted observed rat plasma data reasonably well with simulated plasma concentration-time profiles at 20 mg/kg, 50 mg/kg, and 100 mg/kg doses. Showed reasonable agreement between simulated and observed tissue concentrations in most tissues (brain, lung, liver, kidney, muscle, skin, adipose) at 20 mg/kg dose. Overestimated peak levels in simulated small intestine concentrations and showed a delayed peak not seen in observed data in simulated muscle concentrations at 20 mg/kg dose.

Molecular Weight

165.19

Formula

C₉H₁₁NO₂

CAS No.

55836-69-6

SMILES

O=C(N)C=1C=CC=C(OCC)C1

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation

Handling Instructions (2659 KB)

References

[1]. Lin JH, et al. Physiological pharmacokinetics of ethoxybenzamide based on biochemical data obtained in vitro as well as on physiological data. J Pharmacokinet Biopharm. 1982;10(6):649-661. [Content Brief]

[2]. Czaplewski LG, et al. Antibacterial alkoxybenzamide inhibitors of the essential bacterial cell division protein FtsZ. Bioorg Med Chem Lett. 2009;19(2):524-527. [Content Brief]